Focus Partners Wealth boosted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 18.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 61,389 shares of the company’s stock after purchasing an additional 9,471 shares during the period. Focus Partners Wealth owned approximately 0.08% of IDEXX Laboratories worth $41,411,000 at the end of the most recent reporting period.
A number of other large investors also recently bought and sold shares of IDXX. Empowered Funds LLC raised its stake in IDEXX Laboratories by 6.6% during the first quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock worth $646,000 after purchasing an additional 95 shares during the period. Sivia Capital Partners LLC purchased a new position in IDEXX Laboratories during the second quarter worth approximately $265,000. Jump Financial LLC increased its position in shares of IDEXX Laboratories by 1,006.4% in the second quarter. Jump Financial LLC now owns 5,532 shares of the company’s stock worth $2,967,000 after acquiring an additional 5,032 shares in the last quarter. Cary Street Partners Financial LLC acquired a new stake in shares of IDEXX Laboratories in the second quarter worth $164,000. Finally, Sei Investments Co. increased its position in shares of IDEXX Laboratories by 218.7% in the second quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock worth $64,678,000 after acquiring an additional 82,755 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.
Analyst Upgrades and Downgrades
IDXX has been the subject of several recent research reports. Stifel Nicolaus dropped their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Citigroup initiated coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective for the company. Wall Street Zen raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, UBS Group dropped their price objective on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Seven analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $751.00.
IDEXX Laboratories Price Performance
IDXX opened at $570.00 on Tuesday. The company has a fifty day simple moving average of $563.07 and a 200 day simple moving average of $625.43. The firm has a market cap of $44.96 billion, a price-to-earnings ratio of 41.97, a PEG ratio of 3.07 and a beta of 1.56. IDEXX Laboratories, Inc. has a twelve month low of $506.91 and a twelve month high of $769.98. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19.
IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business’s revenue was up 14.3% on a year-over-year basis. During the same period last year, the business earned $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities research analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.
IDEXX Laboratories Profile
IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.
IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.
Read More
- Five stocks we like better than IDEXX Laboratories
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
